JP Morgan Chase
BIOT

JP Morgan Chase’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

JP Morgan Chase’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,660
Closed -$1.02M – 7511
2022
Q4 		$1.02M Sell
100,660
-99,340
-50% -$995K ﹤0.01% 4026
2022
Q3 		$1.99M Sell
200,000
-1,816,756
-90% -$18M ﹤0.01% 3467
2022
Q2 		$20M Buy
+2,016,756
New +$19.8M ﹤0.01% 1620
2022
Q1 		– Sell
-50,000
Closed -$492K – 7213
2021
Q4 		$492K Buy
+50,000
New +$491K ﹤0.01% 4841

JP Morgan Chase's BIOT Position: Q1 2023 in Review

JP Morgan Chase sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 100,660 shares — an estimated $1.02M sold.

JP Morgan Chase first reported a position in BIOT in Q4 2021 and held it in 4 quarters. The position peaked at $20M in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

  • JP Morgan Chase reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • JP Morgan Chase sold 100,660 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.02M.
  • JP Morgan Chase first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 4 quarters.
  • JP Morgan Chase's Biotech Acquisition Company Class A Ordinary Shares position peaked at $20M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.